-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $4

Benzinga·08/08/2025 11:28:12
Listen to the news
Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $17 to $4.